Source control of PTHrP, such as surgical guidance chemoembolisation with OK432 immunopotentiator and gemcitabine chemotherapy, yields a heterogeneous response in controlling hypercalcaemia, possibly due to the late-stage presentation of GBC with the presence of organ metastasis [34,39]. The gene discussed is PTHLH; the disease is Hypercalcemia.